Ferozsons Laboratories Ltd
Shariah compliantA strong balance sheet, a dividend raised 3 years running, a good business and the price in an uptrend. Priced above its peers.
Working
- Debt is 25% of equity in the latest quarter.
- Revenue up 19% on the same quarter last year.
- Raised every year since FY24, from Rs 3.00 to Rs 5.50.
To watch
- P/E 14.8 against a sector median of 11.9.
- Rs 3.1bn owed by customers. Collections decide how much of the profit turns into cash.
- Yield 1.1% at today's price.
Keep reading FEROZ: business, price trend and value
How good the business is, where its support zone sits, what it may be worth, its health, dividends, peers and latest results open with a free account.
Latest results
Quarter: Jul–Sep 2026In the Jul–Sep 2026 quarter, FEROZ's sales rose 19% to Rs 7.1bn, from Rs 5.9bn, and profit after tax rose 23% to Rs 395.8mn, from Rs 322.0mn (compared with Jul–Sep 2025).
Earnings per share were Rs 7.40, against Rs 5.95 a year earlier.
At Rs 354.39, FEROZ trades at 16.4 times earnings.
- P/E ratio
- 16.4
- Dividend payout
- 0%
- of earnings
- Return on equity
- 8%
- Net margin
- 5.0%
- last 12 months
- Debt to equity
- 0.25
FEROZ quarterly results
Reported figures| Quarter | Sales | Profit after tax | Net margin | EPS | Dividend / share |
|---|---|---|---|---|---|
| Jul–Sep 2026 | Rs 7.1bn | Rs 395.8mn | 5.6% | Rs 7.40 | — |
| Apr–Jun 2026 | Rs 5.8bn | Rs 354.0mn | 6.1% | Rs 5.59 | Rs 5.50 |
| Jan–Mar 2026 | Rs 5.6bn | Rs 207.8mn | 3.7% | Rs 4.78 | — |
| Oct–Dec 2025 | Rs 6.7bn | Rs 344.0mn | 5.1% | Rs 6.19 | — |
| Jul–Sep 2025 | Rs 5.9bn | Rs 322.0mn | 5.4% | Rs 5.95 | — |
| Apr–Jun 2025 | Rs 4.5bn | Rs 255.0mn | 5.7% | Rs 4.74 | Rs 4.00 |
| Jan–Mar 2025 | Rs 5.1bn | Rs 248.0mn | 4.9% | Rs 4.59 | — |
| Oct–Dec 2024 | Rs 4.7bn | Rs 178.0mn | 3.8% | Rs 3.46 | — |
FEROZ annual results and dividends
Reported figures| Year | Sales | Profit after tax | EPS | Dividend / share |
|---|---|---|---|---|
| Year to Jun 2026 | Rs 24.0bn | Rs 1.2bn | Rs 22.51 | Rs 5.50 |
| Year to Jun 2025 | Rs 18.9bn | Rs 922.0mn | Rs 17.86 | Rs 4.00 |
| Year to Jun 2024 | Rs 15.9bn | Rs 755.0mn | Rs 15.72 | Rs 3.00 |
| Year to Jun 2023 | Rs 11.5bn | Rs 297.0mn | Rs 6.24 | — |
| Year to Jun 2022 | Rs 9.3bn | Rs 790.0mn | Rs 16.90 | Rs 4.17 |
Balance sheet and price
Balance sheet as of Sep 2026- Total assets
- Rs 26.2bn
- Shareholders' equity
- Rs 16.0bn
- Cash & bank
- Rs 521.9mn
- Total debt
- Rs 3.9bn
- Current ratio
- 1.91
- 3-month high
- Rs 390.04
- 3-month low
- Rs 316.37
- 1-month change
- +7.1%
- 3-month change
- -0.7%
Read more about FEROZ
Other pharmaceuticals companies
- ABOTAbbot Laboratories (Pakistan) LtdRs 924.15P/E 11.1
- AGPAGP LtdRs 149.85P/E 12.7
- BFBIOBF Biosciences LtdRs 123.20P/E 20.0
- CPHLCiti Pharma LtdRs 63.42P/E 15.7
- CWHCCrestwell Healthcare LimitedRs 21.35
- GLAXOGlaxoSmithKline Pakistan LtdRs 315.00P/E 10.4
- HALEONHaleon Pakistan LtdRs 658.64P/E 12.7
- HINOONHighnoon Laboratories LtdRs 956.76P/E 12.1
- HPLHoehcst Pakistan LtdRs 4056.91P/E 10.4
- IBLHLIBL HealthCare LtdRs 39.86P/E 19.1
- LIVENLiven Pharma LimitedRs 31.47
- MACTERMacter International LtdRs 244.00P/E 15.3
FEROZ: common questions
What is FEROZ's share price?
Ferozsons Laboratories Ltd (FEROZ) last closed at Rs 354.39 on the Pakistan Stock Exchange.
Does FEROZ pay a dividend?
Yes. Ferozsons Laboratories Ltd paid Rs 5.50 per share for the year to Jun 2026.
What were FEROZ's latest results?
In the Jul–Sep 2026 quarter, FEROZ's sales rose 19% to Rs 7.1bn, from Rs 5.9bn, and profit after tax rose 23% to Rs 395.8mn, from Rs 322.0mn (compared with Jul–Sep 2025).
What is FEROZ's P/E ratio?
At Rs 354.39, FEROZ trades at 16.4 times its earnings.
Figures are taken from the company's published financial statements and PSX prices. This page is information, not investment advice.

